GlassScriptPhysician profile
Hoa Thi Xuan Phan
NPI 1255869566
$1,374.77
in general payments reported to CMS, 2019-2025
13 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $162 · 2024: $911 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369.38 | 2024-2025 | Evenity, Prolia, Otezla |
| Gilead Sciences, INC. | $345.54 | 2024-2025 | Vemlidy |
| Xeris Pharmaceuticals, INC. | $169.91 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $90.62 | 2022 | |
| Dexcom, INC. | $75.53 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.53 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $71.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.42 | 2024 | |
| Lilly USA, LLC | $34.59 | 2024 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $25.76 | 2024 | Ingrezza |
| Glaxosmithkline, LLC. | $24.95 | 2024 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $24.90 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $19.00 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hoa Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.